U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
(Check One):
[X] Form 10-K and Form 10-KSB [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q and Form
10-QSB [ ] Form N-SAR
For Period Ended: DECEMBER 31, 1999
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended: _______________________________
- --------------------------------------------------------------------------------
READ ATTACHED INSTRUCTION SHEET BEFORE PREPARING FORM. PLEASE PRINT OR TYPE.
NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION HAS
VERIFIED ANY INFORMATION CONTAINED HEREIN.
- --------------------------------------------------------------------------------
If the notification relates to a portion of the filing checked above, identify
the item(s) to which the notification relates:
PART I REGISTRANT INFORMATION (Official Text)
Full Name of Registrant:
Interleukin Genetics, Inc.
Former Name if Applicable:
N/A
Address of Principal Executive Office (Street and Number)
100 N.E. Loop 410, Suite 820
City, State and Zip Code
San Antonio, Texas 78216
<PAGE>
- --------------------------------------------------------------------------------
PART II RULES 12B-25 (B) AND (C)
- --------------------------------------------------------------------------------
If the subject report could not be filed without unreasonable effort or expense
and the Registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate)
[ ] (a) The response described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense;
[X] (b) The subject annual report, semi-annual report, transition report on
Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof will be filed
on or before the fifteenth calendar day following the prescribed due date;
or the subject quarterly report or transition report on Form 10-Q, or
portion thereof will be filed on or before the fifth calendar day
following the prescribed due date; and
[ ] (c) The accountant's statement or other exhibit required by Rule 12b-25(c)
has been attached if applicable.
- --------------------------------------------------------------------------------
PART III NARRATIVE (Official Text)
- --------------------------------------------------------------------------------
State below in reasonable detail the reasons why the Form 10-K, 11-K, 10-Q,
N-SAR, or the transition report or portion thereof could not be filed within the
prescribed period. (Attach Extra Sheets if Needed)
Certain financial and other information necessary for an accurate and full
completion of the Annual Report on Form 10-K could not be provided within the
prescribed time period without unreasonable effort and expense. The Form 10-K
will be finished promptly and filed on or before the 15th day after its due
date.
<PAGE>
- --------------------------------------------------------------------------------
PART IV OTHER INFORMATION (Official Text)
- --------------------------------------------------------------------------------
(1) Name and telephone number of person to contact in regard to this
notification
KENT FORTNER 210 384-3342
- -------------------------------- --------------- ------------------
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of
1940 during the preceding 12 months or for such shorter period that the
Registrant was required to file such report(s) been filed? If the answer is no,
identify report(s).
[X] Yes [ ] No
(3) Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof?
[X] Yes [ ] No
If so: attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.
See Addendum IV(3)
The Company anticipates that for the year ended December 31, 1999, its results
of operations will reflect a net loss of $6,139,000 and a net loss applicable to
common stock of $11,139,000, or $1.15 per share, compared to a net loss of
$9,508,275 and a net loss applicable to common stock of $9,508,275, or $1.72 per
share, for the year ended December 31, 1998. The increase in the net loss
applicable to common stock for 1999 is primarily due to an amortization charge
of $5,000,000 related to the value of the beneficial conversion feature of the
preferred stock issued and converted to common stock during 1999. The decrease
in the net loss for 1999 as compared to 1998 is primarily due to the Company's
change in marketing strategy from a primarily in-house marketing effort to an
out-sourced marketing effort.
INTERLEUKIN GENETICS, INC.
----------------------------------------
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.
Date MARCH 30, 2000 BY /s/ U. Spencer Allen
-------------------------------------- -----------------------
U. Spencer Allen, Chief
Financial Officer
INSTRUCTION: The form may be signed by an executive officer of the registrant or
by any other duly authorized representative. The name and title of the person
signing the form shall be typed or printed beneath the signature. If the
statement is signed on behalf of the registrant by an authorized representative
(other than an executive officer), evidence of the representative's authority to
sign on behalf of the registrant shall be filed with the form.
ATTENTION
INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACT CONSTITUTE FEDERAL CRIMINAL
VIOLATIONS (SEE 18 U.S.C. 1001).
